相关实验视频

Updated: Jul 27, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

倾向性得分匹配分析比较西斯普拉丁与基于尼达普拉丁的双重剂,用于局部晚期宫癌的并发化疗或放射治疗

Yue Zhang¹, Shasha Fan², Minjie Shan¹

¹Department of Oncology, The Second Xiangya Hospital of Central South University, 139 Middle Renmin Road, Changsha, 410011, Hunan, People's Republic of China.

Scientific reports

|June 8, 2023

概括

基于西斯普拉丁的化疗放射疗法在局部晚期宫癌 (LACC) 中显示出高疗效和安全性. 虽然尼达普拉丁是一种可行的替代品,但西斯普拉丁可能会为LACC患者提供更好的生存结果的趋势.

科学领域:

妇科瘤学妇科瘤学
辐射瘤学辐射瘤学
医学瘤学医学瘤学

背景情况:

局部晚期宫癌 (LACC) 需要有效的治疗策略.
同时化学放射治疗 (CCRT) 是LACC的标准治疗方法.
在CCRT中评估基剂对于优化结果至关重要.

研究的目的:

为了比较cisplatin与nedaplatin在LACC的双重剂CCRT中的疗效和安全性.
评估整体存活率 (OS),无进展存活率 (PFS) 和毒性.
为了确定在这个设置中首选的制剂.

主要方法:

对295名用双重剂CCRT (2015-2020) 治疗的LACC患者 (IIB-IIIC2阶段) 的回顾性分析.
齐斯普拉丁加多塞塔塞尔与尼达普拉丁加多塞塔塞尔组的比较.
倾向性得分 (PS) 匹配用于平衡组比较;卡普兰-梅尔和考克斯模型用于生存分析.

主要成果:

在PS匹配后,西斯普拉丁和尼达普拉丁组之间的客观反应率,5年生存期,PFS或毒性没有显著差异.
在西斯普拉丁组观察到更好的预后趋势.
双剂CCRT在LACC中证明了可行性,安全性和高疗效.

结论:

双剂CCRT是一种可行且有效的LACC治疗方法.
在这种情况下,西斯普拉丁和尼达普拉丁的疗效和安全性表现相似.
建议使用西斯作为首选药物,而尼达普拉丁是对西斯不耐受患者的合适替代品.

更多相关视频

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

相关概念视频

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...